Meeting
2017 ASCO Annual Meeting
Product characteristics associated with in vivo expansion of anti-CD19 CAR T cells in patients treated with axicabtagene ciloleucel (axi-cel).
Authors
Frederick Lundry Locke
H. Lee Moffitt Cancer Canter and Research Institute, Tampa, FL
Frederick Lundry Locke , John Rossi , Sattva Swarup Neelapu , Allen Xue , Marc Better , Xiao Zhang , Armin Ghobadi , Lazaros J. Lekakis , David Bernard Miklos , Caron Alyce Jacobson , Ira Braunschweig , Olalekan O. Oluwole , Tanya Siddiqi , Yi Lin , John Timmerman , Patrick Michael Reagan , Lynn Navale , William Y. Go , Jeffrey S. Wiezorek , Adrian Bot
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research,Immunotherapy
Sub Track
Biomarkers and Correlative Studies from Immunotherapy Trials
Clinical Trial Registration Number
NCT02348216
Citation
J Clin Oncol 35, 2017 (suppl; abstr 3023)
DOI
10.1200/JCO.2017.35.15_suppl.3023
Abstract #
3023
Poster Bd #
118
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Tumor microenvironment associated with increased pretreatment density of activated PD-1+ LAG-3+/− TIM-3− CD8+ T cells facilitates clinical response to axicabtagene ciloleucel (axi-cel) in patients (pts) with large B-cell lymphoma.
First Author: Jerome Galon
Poster
2017 ASCO Annual Meeting
Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19).
First Author: Jerome Galon
Poster
2022 ASCO Quality Care Symposium
Real-world versus clinical trial CAR T outcomes among patients diagnosed with diffuse large B-cell lymphoma.
First Author: Kaitlyn McBride